@prefix dcterms: <http://purl.org/dc/terms/> .
@prefix ns1: <http://www.w3.org/ns/prov#> .
@prefix this: <http://purl.org/np/RA_YLsU-_9ReKinT_QyJOHbLAlnnvrAt6dPA37DgUQxRc> .
@prefix sub: <http://purl.org/np/RA_YLsU-_9ReKinT_QyJOHbLAlnnvrAt6dPA37DgUQxRc#> .
@prefix np: <http://www.nanopub.org/nschema#> .
@prefix rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#> .
@prefix nt: <https://w3id.org/np/o/ntemplate/> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix orcid: <https://orcid.org/> .
@prefix bl: <https://w3id.org/biolink/vocab/> .
@prefix nkg: <https://w3id.org/um/neurodkg/> .
@prefix npx: <http://purl.org/nanopub/x/> .

sub:Head {
  this: np:hasAssertion sub:assertion;
    np:hasProvenance sub:provenance;
    np:hasPublicationInfo sub:pubinfo;
    a np:Nanopublication .
}

sub:assertion {
  <http://purl.obolibrary.org/obo/DOID_2449> bl:category bl:Disease .
  
  sub:association rdf:object <http://purl.obolibrary.org/obo/DOID_2449>;
    rdf:predicate bl:treats;
    rdf:subject <https://identifiers.org/drugbank:DB00104>;
    a rdf:Statement;
    rdfs:label "acromegaly octreotide acetate injection is indicated to reduce blood levels of growth hormone and igf i somatomedin c in acromegaly patients who have had inadequate response to or cannot be treated with surgical resection pituitary irradiation and bromocriptine mesylate at maximally tolerated doses the goal is to achieve normalization of growth hormone and igf i somatomedin c levels see dosage and administration improvement in clinical signs and symptoms or reduction in tumor size or rate of growth were not shown in clinical trials performed with octreotide acetate injection these trials were not optimally designed to detect such effects carcinoid tumors octreotide acetate injection is indicated for the symptomatic treatment of patients with metastatic carcinoid tumors where it suppresses or inhibits the severe diarrhea and flushing episodes associated with the disease octreotide acetate injection studies were not designed to show an effect on the size rate of growth or development of metastases vasoactive intestinal peptide tumors vipomas octreotide acetate injection is indicated for the treatment of the profuse watery diarrhea associated with vip secreting tumors octreotide acetate injection studies were not designed to show an effect on the size rate of growth or development of metastases";
    bl:association_type bl:ChemicalToDiseaseOrPhenotypicFeatureAssociation;
    bl:provided_by <https://w3id.org/um/NeuroDKG>;
    bl:relation nkg:SymptomaticReliefIndication .
  
  <https://identifiers.org/drugbank:DB00104> bl:category bl:Drug .
}

sub:provenance {
  sub:assertion ns1:wasAttributedTo orcid:0000-0002-1468-3557 .
}

sub:pubinfo {
  sub:sig npx:hasAlgorithm "RSA";
    npx:hasPublicKey "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB";
    npx:hasSignature "Qw/dxPFErxuvhc33KVNLgIUvGYXGpxkNVXngA2pZmdnOB+4kts/xgB/xc1dkiqId+3JvoqzIBoGhSroA7lnAjFMqwPN0mDwETVnZifAA8ARoujC/MLONmKJs0PVOaUjCUmQlbgI3QbZyUscNHw9OEkz25tVfG7zhz/3y2Qidd3s=";
    npx:hasSignatureTarget this: .
  
  this: dcterms:created "2021-06-30T09:26:54.277+02:00"^^xsd:dateTime;
    dcterms:creator orcid:0000-0002-1468-3557;
    nt:wasCreatedFromProvenanceTemplate <http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM>;
    nt:wasCreatedFromPubinfoTemplate <http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM>;
    nt:wasCreatedFromTemplate <http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs> .
}